Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Norman Roth

Cardiovascular Disease Wallingford, CT Medical Doctor

NPI 1568828259 CMS profile 7158672

1062 Barnes Rd Ste 300, Wallingford, CT 06492

Open in the dashboard

General payments

$4,424

238 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Norman Roth of Wallingford, CT is reported in the CMS Open Payments database as having received $4,424 across 238 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 66th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $796 38
2024 General $931 45
2023 General $936 43
2022 General $771 51
2021 General $528 32
2020 General $285 18
2019 General $178 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Norman Roth
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Norman Roth were reported at $796. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Norman Roth Cardiovascular Disease median Middle half National median
2019 $178 $450 $127–$1,392 $163
2020 $285 $242 $77–$751 $114
2021 $528 $335 $101–$1,037 $132
2022 $771 $395 $121–$1,211 $149
2023 $936 $443 $136–$1,283 $160
2024 $931 $450 $136–$1,323 $164
2025 $796 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. E.R. Squibb & Sons, L.L.C. $791 56 payments
  2. Novo Nordisk Inc $545 25 payments
  3. Janssen Pharmaceuticals, Inc $510 34 payments
  4. Pfizer Inc. $453 22 payments
  5. AstraZeneca Pharmaceuticals LP $244 15 payments
  6. Novartis Pharmaceuticals Corporation $231 11 payments
  7. CVRx, Inc. $216 3 payments
  8. Amgen Inc. $209 10 payments
  9. Merck Sharp & Dohme Corporation $197 10 payments
  10. Amarin Pharma Inc. $146 10 payments
  11. Other $884 42 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,349 234 payments
  2. Education $57 3 payments
  3. Entertainment $18 1 payment
Products named General payments · program years 2019–2025
  1. XARELTO $510 34 payments
  2. ELIQUIS $396 31 payments
  3. CAMZYOS $376 24 payments
  4. VYNDAQEL $334 15 payments
  5. Ozempic $309 15 payments
  6. RYBELSUS $287 14 payments
  7. VERQUVO $236 12 payments
  8. Wegovy $236 10 payments
  9. Barostim Neo System $216 3 payments
  10. LEQVIO $168 7 payments
  11. Other $1,933 103 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 61 drugs

Part D claims

6,136

Median for Cardiology: 2,533

Drug cost

$1,399,314

Median for Cardiology: $485,213

Branded share of claims

23.4%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 485 $632,297
Entresto Sacubitril/Valsartan Brand 140 $219,380
Jardiance Empagliflozin Brand 77 $120,608
Xarelto Rivaroxaban Brand 75 $111,255
Repatha Sureclick Evolocumab Brand 78 $73,955
Nexlizet Bempedoic Acid/Ezetimibe Brand 29 $31,487
Farxiga Dapagliflozin Propanediol Brand 20 $29,944
Vascepa Icosapent Ethyl Brand 31 $24,533
Brilinta Ticagrelor Brand 18 $21,323
Praluent Pen Alirocumab Brand 22 $21,175

The 10 drugs with the highest cost, of 61 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 57 billing codes

Paid by Medicare

$138,434

Of which drugs: $989

Medicare patients

735

Average age 76

Services billed

2,389

383 women, 352 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 50%
Ischemic heart disease 45%
Chronic kidney disease 40%
Atrial fibrillation 39%
Diabetes 37%
Heart failure 35%
Depression 29%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 33 130 $769

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ELIQUIS
  • PFIZER INC. $68
  • E.R. Squibb & Sons, L.L.C. $59
$128 485 —
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $125
$125 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $99
$99 — —
VYNDAQEL
  • PFIZER INC. $94
$94 — —
FUROSCIX
  • SCPHARMACEUTICALS INC. $65
$65 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

238 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Connecticut

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record